MiNK Therapeutics (NASDAQ:INKT) Raised to Hold at Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Monday.

Several other brokerages have also recently weighed in on INKT. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Price Performance

MiNK Therapeutics stock opened at $11.82 on Monday. The firm has a market capitalization of $55.44 million, a P/E ratio of -3.90 and a beta of 0.34. MiNK Therapeutics has a one year low of $4.56 and a one year high of $76.00. The business has a fifty day moving average price of $11.80 and a 200-day moving average price of $14.33.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. Sell-side analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.